Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 28, 2016
Pharmacy Choice - News - Pharmaceutical Development - August 28, 2016

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 222     Next >>     Go To Page:

8/28/16 - CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its Phase IIa clinical trial "Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischem
8/28/16 - Patent Issued for Compositions and Products Containing S-Equol, and Methods for Their Making (USPTO 9408824)
By a News Reporter-Staff News Editor at Heart Disease Weekly According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Setchell, Kenneth David Reginald; Cole, Sidney John, filed on March 5, 2014, was published online on August 9, 2016. Although the recent FDA approval allowing manufacturer
8/27/16 - Biotie: BTT1023 receives Orphan Drug Designation in the United States [Seven Days (United Arab Emirates)]
-BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m.. The United States Food and Drug Administration has granted Orphan Drug Designation in the United States for Biotie`s BTT1023 drug candidate for the treatment of primary sclerosing cholangitis. The BUTEO study is conducted in partnership with the University of Birmingham, UK
8/27/16 - Is Botox as safe as we think it is?
But a recent study from the University of Wisconsin-Madison has raised fresh doubts about how Botox works in the body. Botox first got FDA approval to treat medical ailments such as muscle spasms, excessive underarm sweating and eyelid tics. In 2002, the FDA approved the drug to be used cosmetically to minimize facial wrinkles, primarily the vertic
8/27/16 - OPINION: Maxwell: Truth? Lie? Time for the Malarkey Meter [Orlando Sentinel]
Ads get rated Minor Malarky, Major Malarkey, Maximum Malarkey or Totally True. The claim: Orlando mother Blanquita Trabold says her daughter was dying of cancer and needed a drug that didn't yet have FDA approval. But can members of Congress really help citizens get access to prescriptions?
8/27/16 - Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA-4 Study of AndexXa (andexanet alfa) at European Society of Cardiology 2016 Congress [Daily Tribune (Bahrain)]
-Portola Pharmaceuticals Inc. today announced that interim results from its ongoing Phase 3 b/4 ANNEXA-4 trial of AndexXa, a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology 2016 Congress, which will take place from August 2731 in Rome. Portola will host an invest
8/27/16 - TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder [Arab News (Saudi Arabia)]
-TG Therapeutics, Inc. today announced that theU.S. As demonstrated with the announcement earlier this week of the orphan drug designation for TGR-1202 in the treatment of CLL, we are committed to building strong proprietary protection around our key compounds, which includes a multi-level patent strategy and orphan drug designations where appropri
8/26/16 - ACETO CORP - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
We are reporting net sales of $558,524 for the year ended June 30, 2016, which represents a 2.1% increase from the $546,951 reported in the comparable prior year. Gross profit for the year ended June 30, 2016 was $142,785 and our gross margin was 25.6% as compared to gross profit of $135,434 and gross margin of 24.8% in the comparable prior year.
8/26/16 - Allergan to Acquire Eye Care Company ForSight VISION5 Adding Peri-Ocular Ring Technology to Company's Leading Portfolio of Innovative Eye Health...
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc, a leading global pharmaceutical company, and ForSight VISION5, a privately held, clinical-stage biotechnology company focused on eye care, announced that they have entered into an agreement under which Allergan will acquire ForSight VISION5. Under the terms of the agreeme
8/26/16 - argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
*Successful Phase 1 multiple ascending dose study of ARGX-113 in healthy volunteers* Phase 2 study in first auto-immune indication planned to start by year-end* Cash position strengthened by $40 M upfront payment from AbbVie and ?30 M private placement Management to host conference call today at 3 pm CET/ 9 am EDT 26 August 2016 Breda, the Nether
8/26/16 - Biotie: BTT1023 receives Orphan Drug Designation in the United States
STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m. Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration has granted Orphan Drug Designation in the United States for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis. The BUTEO study is conducted in...
8/26/16 - BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
-BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial. The study's findings will be released next week at the 2016 Congress of the International Society for Burn Injuries, the quadrennial..
8/26/16 - Can-Fite Reports Financial Results for Six Months Ended June 30, 2016
PETACH TIKVA, Israel, Aug. 26, 2016/ PRNewswire/ Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs.
8/26/16 - Company Profile for Trevena, Inc.
By a News Reporter-Staff News Editor at Drug Week Trevena, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines. Trevena's oliceridine is in Phase 3 development for the management of moderate to severe acute pain, and is the first pain pro
8/26/16 - E-Clinical Solution Software Market Is Expected to Reach USD 6,515.3 Million in 2020, Growing at a CAGR of 13.8%
North America is estimated at USD 1,773.9 million in 2014 and is expected to reach USD 3,622.5 million in 2020, growing at a CAGR of 12.6% from 2014 to 2020. Albany, NY 08/26/2016 E-clinical solution is a software that helps researchers with new ways to manage and analyze clinical data. It helps clinical research organizations, pharmaceutical
8/26/16 - First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union - Press Release issued by HemispherxBiopharma [Pakistan Press International]
HemispherxBiopharma, Inc., announced that it has received approval of its New Drug Application from AdministracionNacional de Medicamentos, Alimentos y TecnologiaMedica for commercial sale of rintatolimod in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome. The product will be marketed by GP...
8/26/16 - Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
Flex Pharma, Inc. announced today that W. Larry Kenney, Ph.D., Professor of Physiology and Kinesiology at Penn State University, has joined the Company s Scientific Advisory Board. Flex Pharma is a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps, spasms associated with severe neuromuscular conditio
8/26/16 - Frederick cancer center taking patients for nationwide trial [The Frederick News-Post, Md.]
The National Cancer Institute's Molecular Analysis for Therapy Choice, or MATCH, is a clinical trial that matches genetic abnormalities in patients' tumors to drugs that target those abnormalities. Five patients have been screened through the Frederick Regional Health System's Cancer Therapy Center on Seventh Street. Patrick Mansky, the principal..
8/26/16 - Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
Release date- 25082016- NORCROSS, Ga- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2 a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. In May, the company announced significant improvement in PASI s
8/26/16 - Mallinckrodt Receives FDA Fast-Track Designation for Synacthen Depot IND Application
Release date- 25082016- CHESTERFIELD, United Kingdom- Mallinckrodt plc, a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration has granted the company's request for a Fast Track designation for its Investigational New Drug application for Synacthen Depot in the treatment of Duchenne muscular dystrop
8/26/16 - Mallinckrodt's muscular dystrophy drug receives FDA fast track designation
For the treatment of Duchenne muscular dystrophy (DMD), Synacthen Depot is a synthetic 24 amino acid melanocortin receptor agonist. Outside the US, it...
8/26/16 - Metrics Contract Services Invests in New Stability Storage Facility, Tripling Current Capacity
Stability storage provides specific environmental conditions for drug substance and drug products meeting International Conference on Harmonisation standards. The parent company of Metrics, Mayne Pharma, is investing $80 million to significantly expand facilities and equipment, including 10- plus new analytical labs and formulation development...
8/26/16 - Nasal spray safe, effective anesthetic for dental work
The U.S. Food and Drug Administration has approved Kovanaze, a nasal spray anesthetic for use in restorative dental work after it was shown to be safe and effective in clinical trials. Kovanaze, which is a combination of tetracaine and the nasal decongestant oxymetazoline, was approved by the FDA for use with patients over 88 pounds, though the com
8/26/16 - PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul FDA Submission [Daily Star, The (Lebanon)]
-PetLife Pharmaceuticals, Inc., a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the signing of a contract with InnoVision Therapeutics, a major step towards the Center for Veterinary Medicine/ FDA testing and approval process for Vitalzul. We are pleased to be working
8/26/16 - PhytoPain Pharma Announces Appointments to Its Scientific and Clinical Advisory Board
PhytoPain Pharma Inc., a subsidiary of GrowPros Cannabis Ventures Inc., is pleased to announce the creation of its Scientific and Clinical Advisory Board. PPP also intends on submitting the clinical protocol to the US Food& Drug Administration for review. PPP is developing this prescription drug product for both the Canadian and USA market and inte
Articles(s): 1 - 25 of 222     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415